Alnylam Days Payables Outstanding vs Operating Cash Flow Per Share Analysis

ALNY Stock  USD 253.91  1.98  0.77%   
Alnylam Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alnylam Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alnylam Pharmaceuticals is a good investment. Please check the relationship between Alnylam Pharmaceuticals Days Payables Outstanding and its Operating Cash Flow Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Days Payables Outstanding vs Operating Cash Flow Per Share

Days Payables Outstanding vs Operating Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alnylam Pharmaceuticals Days Payables Outstanding account and Operating Cash Flow Per Share. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Alnylam Pharmaceuticals' Days Payables Outstanding and Operating Cash Flow Per Share is -0.38. Overlapping area represents the amount of variation of Days Payables Outstanding that can explain the historical movement of Operating Cash Flow Per Share in the same time period over historical financial statements of Alnylam Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Alnylam Pharmaceuticals' Days Payables Outstanding and Operating Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Payables Outstanding of Alnylam Pharmaceuticals are associated (or correlated) with its Operating Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Cash Flow Per Share has no effect on the direction of Days Payables Outstanding i.e., Alnylam Pharmaceuticals' Days Payables Outstanding and Operating Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

-0.38
Relationship DirectionNegative 
Relationship StrengthInsignificant

Days Payables Outstanding

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.
Most indicators from Alnylam Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 7.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.41 in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit704.1M868.6M1.5B1.6B
Total Revenue844.3M1.0B1.8B1.9B

Alnylam Pharmaceuticals fundamental ratios Correlations

0.910.92-0.10.950.6-0.970.750.640.92-0.360.720.980.780.960.870.390.910.960.990.960.780.70.430.850.98
0.910.83-0.450.890.84-0.960.590.50.84-0.540.740.860.560.890.980.290.980.970.90.930.950.60.230.960.89
0.920.83-0.130.960.59-0.890.660.430.94-0.220.580.850.70.910.790.480.860.920.870.920.680.790.70.740.89
-0.1-0.45-0.13-0.17-0.710.260.050.2-0.130.36-0.260.010.29-0.11-0.560.03-0.49-0.31-0.08-0.19-0.58-0.20.27-0.56-0.02
0.950.890.96-0.170.64-0.960.770.450.96-0.280.650.880.730.950.850.450.90.960.910.980.730.720.540.820.95
0.60.840.59-0.710.64-0.710.270.030.59-0.60.670.510.170.670.840.150.810.770.580.70.910.410.050.830.57
-0.97-0.96-0.890.26-0.96-0.71-0.77-0.55-0.90.43-0.76-0.93-0.74-0.95-0.93-0.33-0.96-0.98-0.96-0.98-0.84-0.67-0.33-0.92-0.97
0.750.590.660.050.770.27-0.770.40.730.00.70.720.840.720.590.260.630.680.720.750.370.560.270.620.79
0.640.50.430.20.450.03-0.550.40.37-0.40.340.750.60.460.47-0.010.480.470.710.470.440.370.090.480.62
0.920.840.94-0.130.960.59-0.90.730.37-0.120.620.830.720.910.790.630.860.930.850.930.650.620.570.730.9
-0.36-0.54-0.220.36-0.28-0.60.430.0-0.4-0.12-0.4-0.41-0.05-0.34-0.520.35-0.46-0.43-0.43-0.39-0.71-0.180.22-0.57-0.37
0.720.740.58-0.260.650.67-0.760.70.340.62-0.40.710.550.710.740.020.740.730.730.710.720.480.030.80.73
0.980.860.850.010.880.51-0.930.720.750.83-0.410.710.80.930.810.260.850.90.990.90.740.680.370.810.97
0.780.560.70.290.730.17-0.740.840.60.72-0.050.550.80.720.510.330.570.660.780.720.380.520.460.50.82
0.960.890.91-0.110.950.67-0.950.720.460.91-0.340.710.930.720.840.380.890.960.940.960.750.710.450.820.96
0.870.980.79-0.560.850.84-0.930.590.470.79-0.520.740.810.510.840.240.990.930.860.880.940.620.170.990.83
0.390.290.480.030.450.15-0.330.26-0.010.630.350.020.260.330.380.240.330.40.280.380.110.170.490.110.34
0.910.980.86-0.490.90.81-0.960.630.480.86-0.460.740.850.570.890.990.330.970.90.910.910.690.270.970.87
0.960.970.92-0.310.960.77-0.980.680.470.93-0.430.730.90.660.960.930.40.970.930.980.870.690.380.90.94
0.990.90.87-0.080.910.58-0.960.720.710.85-0.430.730.990.780.940.860.280.90.930.930.790.690.350.860.97
0.960.930.92-0.190.980.7-0.980.750.470.93-0.390.710.90.720.960.880.380.910.980.930.790.670.420.850.97
0.780.950.68-0.580.730.91-0.840.370.440.65-0.710.720.740.380.750.940.110.910.870.790.790.50.060.930.74
0.70.60.79-0.20.720.41-0.670.560.370.62-0.180.480.680.520.710.620.170.690.690.690.670.50.540.630.64
0.430.230.70.270.540.05-0.330.270.090.570.220.030.370.460.450.170.490.270.380.350.420.060.540.10.41
0.850.960.74-0.560.820.83-0.920.620.480.73-0.570.80.810.50.820.990.110.970.90.860.850.930.630.10.81
0.980.890.89-0.020.950.57-0.970.790.620.9-0.370.730.970.820.960.830.340.870.940.970.970.740.640.410.81
Click cells to compare fundamentals

Alnylam Pharmaceuticals Account Relationship Matchups

Alnylam Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets2.4B3.4B3.6B3.5B3.8B4.0B
Other Current Liab206.5M355.9M395.2M545.5M713.0M748.7M
Total Current Liabilities956.4M1.1B1.2B767.9M967.8M1.0B
Total Stockholder Equity1.4B1.0B588.2M(158.2M)(220.6M)(209.6M)
Property Plant And Equipment Net646.4M706.5M733.6M738.6M725.8M762.1M
Net Debt(243.4M)24.6M177.6M453.9M1.9B2.0B
Retained Earnings(3.7B)(4.6B)(5.4B)(6.6B)(7.0B)(6.7B)
Accounts Payable49.9M52.0M73.4M98.1M55.5M28.9M
Cash547.2M496.6M820.0M866.4M812.7M853.3M
Non Current Assets Total661.2M1.2B774.5M854.1M847.2M889.5M
Non Currrent Assets Other18.1M500M40.9M115.5M(576.4M)(547.6M)
Other Assets32.9M40.7M101.1M115.5M132.8M139.4M
Cash And Short Term Investments1.5B1.9B2.4B2.2B2.4B2.6B
Common Stock Shares Outstanding109.3M115.0M118.5M121.7M124.9M70.4M
Short Term Investments989.0M1.4B1.6B1.3B1.6B1.7B
Liabilities And Stockholders Equity2.4B3.4B3.6B3.5B3.8B4.0B
Non Current Liabilities Total603.8M1.3B1.9B2.9B3.1B3.2B
Other Current Assets98.4M625.5M88.1M132.9M126.4M94.5M
Total Liab956.4M2.4B3.1B3.7B4.1B4.3B
Property Plant And Equipment Gross425.2M706.5M733.6M738.6M948.9M996.3M
Total Current Assets1.7B2.2B2.9B2.7B3.0B3.1B
Accumulated Other Comprehensive Income(36.5M)(43.6M)(33.3M)(44.7M)(23.4M)(22.2M)
Property Plant Equipment425.2M465.0M502.0M523.5M602.0M632.1M
Short Long Term Debt Total303.8M521.2M997.6M1.3B2.7B2.8B
Other Liab327.7M352.3M1.4B406.4M467.3M490.7M
Current Deferred Revenue396.2M352.3M301.8M42.1M102.8M119.3M
Other Stockholder Equity5.2B5.6B6.1B6.5B6.8B7.2B
Short Term Debt303.8M50.2M77.6M82.3M96.5M101.3M
Net Receivables43.0M102.4M198.6M238.0M327.8M344.2M
Common Stock Total Equity1.1M1.2M1.2M1.2M1.4M770.9K
Common Stock1.1M1.2M1.2M1.2M1.3M801.6K
Net Tangible Assets1.4B1.0B588.2M(158.2M)(182.0M)(172.9M)
Retained Earnings Total Equity(3.7B)(4.6B)(5.4B)(6.6B)(5.9B)(5.6B)
Capital Surpluse5.2B5.6B6.1B6.5B7.4B7.8B
Inventory56.3M92.3M122.7M129.0M89.1M93.6M
Non Current Liabilities Other603.8M1.6B1.7B1.5B1.6B1.7B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.